2022 Stronger - PH337 - The Importance, Implementation and Optimization of Biosimilars: Proven Strategies - On Demand
This session features a panel of health care leaders who will share their experiences and insights into the implementation, use and management of biosimilars.
The pharmacy team at Baptist Cancer Center (BCC) has been successful in optimizing biosimilar use across 17 outpatient oncology offices. In fiscal year 2021, the BCC pharmacy surpassed its goal by increasing overall biosimilar utilization from 58% to 79% — saving $9 million in drug purchase expense. BCC also successfully converted first-to-market biosimilars to newer, lower-priced products.
Biologics are one of the highest expenses at Sharp HealthCare, representing over 40% of pharmaceutical spend. With few opportunities to optimize savings in the treatment of chronic diseases and cancers, the Infusion Center and Pharmacy Workgroup formed to expand the use of biosimilars. The group was successful due to multidisciplinary collaboration; provider education; and standardized, efficient processes. Biosimilar use is above 90%, resulting in a $6 million cost savings in two years.
Froedtert & the Medical College of Wisconsin has successfully addressed challenges around the use of biosimilars, such as prescriber and patient misperceptions, variability in insurance coverage, and revenue cycle complexities — all of which make biosimilar adoption more difficult to achieve. Leaders will describe a novel strategy to address these challenges by expediting formulary inclusion of biosimilars and maximizing their value for patients and the health system. Interdisciplinary collaboration, leadership support and pharmacy revenue assessment are important for initiative success.
Join this session to learn how to optimize the use of biosimilars at your organization.
- Other Healthcare Professionals
Describe how to design a process for biosimilar implementation and utilization across the health system.
Explain the barriers to and challenges of implementing a biosimilar conversion process within an integrated health care system.
List various metrics needed to maintain and monitor success of the biosimilar conversion process.
Alexander Quesenberry, PharmD, BCOP, Director of Pharmacy, Baptist Memorial Health Care Corp/Baptist Cancer Center, Memphis, TN
Susan Sachs, PharmD, Manager of Pharmacy Finance and Regulatory Compliance, Sharp HealthCare, San Diego, CA
Nilay Pradhan, PharmD, BCACP, Senior Specialist, Pharmacy Contracts, Sharp HealthCare, San Diego, CA
Adam Biggs, PharmD, Pharmacist, Center for Medication Utilization, Froedtert Health, Milwaukee, WI
Shannon Werner, PharmD, Coordinator, Center for Medication Utilization, Froedtert Health, Milwaukee, WI
Vizient, Inc. designates this enduring material for a maximum of 1.0 contact hours for Pharmacists.
Universal Activity Number: JA0006103-0000-22-093-H04-P
Other Healthcare Professionals (General CE Credit)
Vizient, Inc. will award a maximum of 1.0 contact hours to all other healthcare professionals who successfully complete the activity. These individuals will receive a Certificate of Participation indicating the maximum credits available.
Many state licensing boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 1.00 ACPE Pharmacist
- 1.00 General CEU – Attendance